Dr. Xuetao Cao
雪涛曹博士
中国医学科学院（CAMS）主席
当前位置：理事长，中国医学科学院，北京，中国。
简介：雪涛曹博士，获得博士学位 来自第二军医大学（上海，
中国）在1990年，他成为了在免疫学教授，于1992年在第二军医大学和
免疫学研究所于2001年在同一大学的主任，他现在是教授，主任
医学免疫学（2006.5-），而中国研究院院长的中国国家重点实验室
医学（2011.8-）。他当选为中国工程院院士的成员在2005年，他是
中国免疫学会（2006.11-），免疫学的FIMSA（联合会会长会长
在亚洲和大洋洲的社会）（2012.3-），和总裁全球联盟的慢性疾病（2013.12-）。
他是主编，首席细胞与分子免疫学，以及编委细胞，年
免疫学，科学转化医学，e生活等方面的评论作为通讯作者，他出版
超过220的原始文件在同行评审期刊上，包括手机，科学，NAT免疫，免疫，
癌细胞，免疫，实验医学，PNAS等他的H指数是56（谷歌学术搜索）。
His major interests are innate signaling in infection and inflammation, immune regulation, immunotherapy
and gene therapy. He has made important contributions to the understanding of innate signaling in
immunity and inflammation, identification of regulatory immune cell subsets and new immune molecules
in immune response and cancer. His group has identified and functionally characterized 22 novel molecules
from a human dendritic cell (DC) cDnA library. He identified several subsets of immune cells with
regulatory function, for example, he found that splenic stroma can drive mature DC to further proliferate
and differentiate into IalowCD11bhigh regulatory DC subset which can feedback inhibit immune response.
This subset of regulatory DC can also drive generation of new regulatory immune cell subsets including
immunosuppressive memory T cells (IL-4hiIL-10hiCD44hiCD62L-CCR7-) and regulatory B cells (IL-
10hiCD19 hiFcgIIbhi), forming feedback loop for the control of immune response. He has identified
important mediators and regulators of TLR/RIG-I-triggered innate inflammatory response. For example,
he discovered E3 ligase Nrdp1/DRP from human DC cDNA library (1998) and then identified Nrdp1 as the
enhancer of type I interferon production. He proposed that Siglec-G, mouse homolog of human Siglec-10
he independently cloned from human DC library, can selectively help RnA viruses escape innate immune
response by promoting RIG-I degradation. He showed that membrane MHC-I and intracellular MHC-II
molecules can negatively and positively regulate TLR-triggered response. He reported several microRnAs
as regulators of type I interferon production and function. He investigated several new approaches to cancer
immunotherapy in basic and clinics.